Read on Twitter
NEW PAPER ALERTI'm so excited to share our latest @TaraballiPhD
cancer nanomedicine study, just accepted now in
@ACS_ABM , @ACS_AMI! A tread
(1/7)https://pubs.acs.org/doi/10.1021/acsabm.0c00685#.X0UOnCr9Lc8.twitter
Trying to learn from @OdedRechavi how to do it right.
77 million years ago dinosaur diagnosed with bone cancer that afflicts humans today (2/7) https://www.cnn.com/2020/08/03/americas/dinosaur-fossil-cancer-first-scn/index.html
Ponatinib (Pon) is a multi-tyrosine kinase inhibitor that demonstrated high efficiency for treating cancer. However, severe side effects caused by Pon off targeting effects prevent its extensive use. (3/7)
We have decided to mimic the main way Pon is transported in our blood -> Bovine Serum Albumin (BSA) (4/7)
We have demonstrated promising dose-response results on two different murine osteosarcoma (OS) cell lines, F420 and RF379 (5/7)
By fabricating more than 30 biomimetic nanoparticles, fabricated by three different users we also demonstrated the scalability potential of our fabrication method. (6/7)
I want to thank our amazing team from:
@HMethodistMD- @TaraballiPhD @Federic12957061 @MatteoMassaro3 @ac_ewing03 @GENETICA75 @EnnioTasciotti
@TexasChildrens- Ha Ram Kin and Jason Yustein
@TheZingerFamily- for their endless support and love.
(7/7)
@HMethodistMD- @TaraballiPhD @Federic12957061 @MatteoMassaro3 @ac_ewing03 @GENETICA75 @EnnioTasciotti
@TexasChildrens- Ha Ram Kin and Jason Yustein
@TheZingerFamily- for their endless support and love.
(7/7)
